Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Open access
Jain, Tania, Bar, Merav, Kansagra, Ankit J., Chong, Elise A., Hashmi, Shahrukh K., Neelapu, Sattva S., Byrne, Michael, Jacoby, Elad, Lazaryan, Aleksandr, Jacobson, Caron A., Ansell, Stephen M., Awan, Farrukh T., Burns, Linda, Bachanova, Veronika, Bollard, Catherine M., Carpenter, Paul A., DiPersio, John F., Hamadani, Mehdi, Heslop, Helen E., Hill, Joshua A., Komanduri, Krishna V., Kovitz, Craig A., Lazarus, Hillard M., Serrette, Justin M., Mohty, Mohamad, Miklos, David, Nagler, Arnon, Pavletic, Steven Z., Savani, Bipin N., Schuster, Stephen J., Kharfan-Dabaja, Mohamed A., Perales, Miguel-Angel, Lin, Yi·2019·Biology of Blood and Marrow Transplantation

Abstract

Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2019.08.015

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 87

  1. Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
  2. June, 2018, Chimeric antigen receptor therapy, N Engl J Med, 379, 64, 10.1056/NEJMra1706169 · DOI · Paper page
  3. Kansagra, 2019, Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 25, e76, 10.1016/j.bbmt.2018.12.068 · DOI
  4. Garcia Munoz, 2014, Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab, Ann Hematol, 93, 1879, 10.1007/s00277-014-2135-8 · DOI
  5. Ito, 2015, Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma, Leuk Lymph, 56, 1123, 10.3109/10428194.2014.921298 · doi:10.3109/10428194.2014.921298
  6. Yutaka, 2015, Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma, Leuk Lymph, 56, 3216, 10.3109/10428194.2015.1026818 · DOI
  7. Jacobson, 2018, Axicabtagene ciloleucel in the real world: outcomes and predictors of response, Resist Toxic, 132, 92
  8. Jain, 2019, Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma, Leukemia, 10.1038/s41375-019-0476-y · DOI
  9. Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025 · DOI · Paper page
  10. Kochenderfer, 2013, Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation, Blood, 122, 4129, 10.1182/blood-2013-08-519413 · DOI · Paper page
  11. Nastoupil, 2018, Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience, Blood, 132, 91, 10.1182/blood-2018-99-114152 · DOI
  12. Das, 2019, Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers, Cancer Discov, 9, 492, 10.1158/2159-8290.CD-18-1314 · DOI · Paper page
  13. Locke, 2018, Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma, J Clin Oncol, 36, 3003, 10.1200/JCO.2018.36.15_suppl.3003 · DOI
  14. Frigault, 2019, Tisagenlecleucel CAR-T cell therapy in secondary CNS lymphoma, Blood, 134, 860, 10.1182/blood.2019001694 · DOI · Paper page
  15. Abramson, 2018, Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL, J Clin Oncol, 36, 7505, 10.1200/JCO.2018.36.15_suppl.7505 · DOI · Paper page
  16. Abramson, 2017, Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma, N Engl J Med, 377, 783, 10.1056/NEJMc1704610 · DOI · Paper page
  17. Schuster, 2019, CD19-directed CAR T cells gain traction, Lancet Oncol, 20, 2, 10.1016/S1470-2045(18)30900-8 · DOI
  18. Jain, 2018, Radiation therapy as a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel, Blood, 132, 4220, 10.1182/blood-2018-99-117133 · doi:10.1182/blood-2018-99-117133
  19. Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 · DOI · Paper page
  20. Otahal, 2016, Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells, Oncoimmunology, 5, 10.1080/2162402X.2015.1115940 · DOI
  21. Ruella, 2016, The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma, Clin Cancer Res, 22, 2684, 10.1158/1078-0432.CCR-15-1527 · DOI · Paper page
  22. Wilson, 2015, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, Nat Med, 21, 922, 10.1038/nm.3884 · DOI · Paper page
  23. Sauter, 2019, CD19 CAR T cells following autologous transplantation in poor risk relapsed and refractory B cell non-Hodgkin lymphoma, Blood, 10.1182/blood.2018883421 · DOI
  24. Diab, 2013, Enhanced responses to tumor immunization following total body irradiation are time-dependent, PLoS One, 8, e82496, 10.1371/journal.pone.0082496 · DOI
  25. Klebanoff, 2005, Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy, Trends Immunol, 26, 111, 10.1016/j.it.2004.12.003 · DOI · Paper page
  26. Lee, 2012, The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer, Clin Cancer Res, 18, 2780, 10.1158/1078-0432.CCR-11-1920 · DOI
  27. Neelapu, 2019, CAR-T efficacy: is conditioning the key?, Blood, 133, 1799, 10.1182/blood-2019-03-900928 · DOI
  28. Ninomiya, 2015, Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs, Blood, 125, 3905, 10.1182/blood-2015-01-621474 · DOI · Paper page
  29. Faramand, 2018, Prediction of CAR T-related toxicities in R/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements, Blood, 132, 95, 10.1182/blood-2018-99-116539 · DOI
  30. Bishop, 2019, Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion, Blood Adv, 3, 2230, 10.1182/bloodadvances.2019000151 · DOI
  31. Dreger, 2019, PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL, Blood Adv, 3, 360, 10.1182/bloodadvances.2018027748 · DOI
  32. van Kampen, 2011, Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry, J Clin Oncol, 29, 1342, 10.1200/JCO.2010.30.2596 · DOI · Paper page
  33. Kyriakou, 2019, The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party, Biol Blood Marrow Transplant, 25, 86, 10.1016/j.bbmt.2018.08.025 · DOI
  34. Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 · DOI · Paper page
  35. Van Den Neste, 2016, Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study, Bone Marrow Transplant, 51, 51, 10.1038/bmt.2015.213 · DOI · Paper page
  36. Epperla, 2018, Survival of lymphoma patients experiencing relapse or progression after an allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 24, 983, 10.1016/j.bbmt.2018.01.015 · doi:10.1016/j.bbmt.2018.01.015
  37. Wudhikarn, 2011, Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome, Biol Blood Marrow Transplant, 17, 1497, 10.1016/j.bbmt.2011.02.009 · DOI
  38. Brudno, 2016, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease, J Clin Oncol, 34, 1112, 10.1200/JCO.2015.64.5929 · DOI · Paper page
  39. Cruz, 2013, Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study, Blood, 122, 2965, 10.1182/blood-2013-06-506741 · DOI · Paper page
  40. Kebriaei, 2016, Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J Clin Invest, 126, 3363, 10.1172/JCI86721 · DOI · Paper page
  41. Dai, 2015, Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia, Oncoimmunology, 4, 10.1080/2162402X.2015.1027469 · DOI · Paper page
  42. Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208 · DOI · Paper page
  43. Smith, 2018, Posttransplant chimeric antigen receptor therapy, Blood, 131, 1045, 10.1182/blood-2017-08-752121 · DOI
  44. Frey, 2019, Cytokine release syndrome with chimeric antigen receptor T cell therapy, Biol Blood Marrow Transplant, 25, e123, 10.1016/j.bbmt.2018.12.756 · DOI · Paper page
  45. Lee, 2018, ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant, 25, 625, 10.1016/j.bbmt.2018.12.758 · DOI · Paper page
  46. Heslop, 2019, Harmonizing immune effector toxicity reporting, Biol Blood Marrow Transplant, 25, e121, 10.1016/j.bbmt.2019.01.001 · doi:10.1016/j.bbmt.2019.01.001
  47. Brudno, 2019, Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management, Blood Rev, 34, 45, 10.1016/j.blre.2018.11.002 · DOI · Paper page
  48. Neelapu, 2018, Chimeric antigen receptor T-cell therapy—assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148 · DOI · Paper page
  49. Locke, 2017, Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL), Blood, 1, 1547, 10.1182/blood.V130.Suppl_1.1547.1547 · DOI · Paper page
  50. Santomasso, 2018, Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia, Cancer Discov, 8, 958, 10.1158/2159-8290.CD-17-1319 · DOI · Paper page
  51. Locke, 2017, Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL), J Clin Oncol, 35, 7512, 10.1200/JCO.2017.35.15_suppl.7512 · DOI
  52. Wang, 2019, Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma, Biol Blood Marrow Transplant, 25, 1092, 10.1016/j.bbmt.2019.02.008 · DOI
  53. Mahmoudjafari, 2019, American Society for Blood and Marrow Transplantation pharmacy special interest group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States, Biol Blood Marrow Transplant, 25, 26, 10.1016/j.bbmt.2018.09.024 · DOI
  54. Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 7, 1404, 10.1158/2159-8290.CD-17-0698 · DOI · Paper page
  55. Gust, 2018, Neurotoxicity associated with CD19-targeted CAR-T cell therapies, CNS Drugs, 32, 1091, 10.1007/s40263-018-0582-9 · DOI · Paper page
  56. Cordeiro, 2018, Late effects of CD19-targeted CAR-T cell therapy, Blood, 132, 223, 10.1182/blood-2018-99-112023 · doi:10.1182/blood-2018-99-112023
  57. Fried, 2019, Early and late hematologic toxicity following CD19 CAR-T cells, Bone Marrow Transplant, 10.1038/s41409-019-0487-3 · DOI · Paper page
  58. Neelapu, 2018, 2-Year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma, Blood, 132, 2967, 10.1182/blood-2018-99-111368 · DOI
  59. Kochenderfer, 2017, Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy, Mol Ther, 25, 2245, 10.1016/j.ymthe.2017.07.004 · DOI · Paper page
  60. Hill, 2018, Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy, Blood, 131, 121, 10.1182/blood-2017-07-793760 · DOI · Paper page
  61. 2018, ASBMT and CBMTG release choosing wisely BMT recommendations, Biol Blood Marrow Transplant, 24, 880, 10.1016/j.bbmt.2018.03.020 · doi:10.1016/j.bbmt.2018.03.020
  62. Hill, 2019, CAR-T— and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy, Blood Rev, 10.1016/j.blre.2019.100596 · DOI · Paper page
  63. Strati, 2019, Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection, Blood, 133, 2800, 10.1182/blood.2019000888 · DOI
  64. Laetsch, 2018, False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy, Blood, 131, 2596, 10.1182/blood-2017-12-822940 · DOI
  65. Ahuja, 2008, Maintenance of the plasma cell pool is independent of memory B cells, Proc Natl Acad Sci USA, 105, 4802, 10.1073/pnas.0800555105 · DOI · Paper page
  66. Slifka, 1998, Humoral immunity due to long-lived plasma cells, Immunity, 8, 363, 10.1016/S1074-7613(00)80541-5 · DOI · Paper page
  67. Bhoj, 2016, Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy, Blood, 128, 360, 10.1182/blood-2016-01-694356 · DOI · Paper page
  68. Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800 · DOI · Paper page
  69. Shah, 2018, Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas, Cytotherapy, 20, 1415, 10.1016/j.jcyt.2018.10.003 · doi:10.1016/j.jcyt.2018.10.003
  70. Chong, 2019, CD19-directed CAR T cell therapy (CTL019) for relapsed/refractory diffuse large B-cell and follicular lymphomas: four year outcomes. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Hematol Oncol, 37, 137, 10.1002/hon.96_2629 · doi:10.1002/hon.96_2629
  71. Frank, 2019, Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis, J Clin Oncol, 37, 7552, 10.1200/JCO.2019.37.15_suppl.7552 · doi:10.1200/jco.2019.37.15_suppl.7552
  72. Neelapu, 2017, Long-term follow-up ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-hodgkin lymphoma (NHL), Blood, 130, 578
  73. Yu, 2017, Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma, Am J Hematol, 92, E11, 10.1002/ajh.24594 · DOI
  74. Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245 · DOI · Paper page
  75. Byrne, 2019, Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy, Biol Blood Marrow Transplant, 10.1016/j.bbmt.2019.06.036 · DOI
  76. Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol Ther Oncol, 3, 16011, 10.1038/mto.2016.11 · DOI · Paper page
  77. Zheng, 2018, Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts, Drug Discov Today, 23, 1175, 10.1016/j.drudis.2018.02.012 · DOI · Paper page
  78. Cornetta, 2018, Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products, Mol Ther, 26, 280, 10.1016/j.ymthe.2017.09.008 · DOI · Paper page
  79. Colovos, 2012, Safety and stability of retrovirally transduced chimeric antigen receptor T cells, Immunotherapy, 4, 899, 10.2217/imt.12.91 · DOI
  80. Li, 2019, Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma, JCI Insight, 5, 1
  81. Ramos, 2017, Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes, J Clin Invest, 127, 3462, 10.1172/JCI94306 · DOI · Paper page
  82. Salmikangas, 2018, Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy—moving target for industry?, Pharm Res, 35, 152, 10.1007/s11095-018-2436-z · DOI
  83. Qasim, 2017, Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product in a first-in-human trial (PALL) in pediatric patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia, Blood, 130, 1271
  84. Sakemura, 2016, A tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration, Cancer Immunol Res, 4, 658, 10.1158/2326-6066.CIR-16-0043 · DOI · Paper page
  85. Bishop, 2018, PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts, Mol Ther, 26, 1883, 10.1016/j.ymthe.2018.05.007 · DOI
  86. Ptackova, 2018, A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21, Cytotherapy, 20, 507, 10.1016/j.jcyt.2017.10.001 · DOI
  87. Tipanee, 2017, Transposons: moving forward from preclinical studies to clinical trials, Hum Gene Ther, 28, 1087, 10.1089/hum.2017.128 · DOI

Cited by

See all 191

Metadata

Authors
Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., Ansell, S. M., Awan, F. T., Burns, L., Bachanova, V., Bollard, C. M., Carpenter, P. A., DiPersio, J. F., Hamadani, M., Heslop, H. E., Hill, J. A., Komanduri, K. V., Kovitz, C. A., Lazarus, H. M., Serrette, J. M., Mohty, M., Miklos, D., Nagler, A., Pavletic, S. Z., Savani, B. N., Schuster, S. J., Kharfan-Dabaja, M. A., Perales, M.-A., & Lin, Y.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2019-12
Volume
25
Issue
12
Pages
2305-2321
ISSN
1083-8791 (ISSN-L)
OpenAlex
W2969216121
Cited by
191
References
12
FWCI
9.16
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. https://app.cochat.ai/papers/10.1016/j.bbmt.2019.08.015
The paper
Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., Ansell, S. M., Awan, F. T., Burns, L., Bachanova, V., Bollard, C. M., Carpenter, P. A., DiPersio, J. F., Hamadani, M., Heslop, H. E., . . . Lin, Y. (2019). Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.08.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.